Dr. Tanya B. Dorff, MD | Duarte, CA ...

Dr. Tanya Dorff, MD

Claim this profile

City of Hope Medical Center

Expert in Prostate Cancer
Studies Skin Cancer
15 reported clinical trials
37 drugs studied

Area of expertise

1Prostate Cancer
Global Leader
Tanya Dorff, MD has run 13 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
PSCA positive
PSA positive
2Skin Cancer
Tanya Dorff, MD has run 6 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
PSCA positive
PSA positive

Affiliated Hospitals

Image of trial facility.
City Of Hope Medical Center
Image of trial facility.
City Of Hope

Clinical Trials Tanya Dorff, MD is currently running

Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Image of trial facility.

Hormone + Radiation Therapy

for Prostate Cancer

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria

More about Tanya Dorff, MD

Clinical Trial Related7 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Tanya Dorff, MD has experience with
  • Abiraterone Acetate
  • Prednisone
  • Apalutamide
  • Degarelix
  • Bicalutamide
  • Triptorelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tanya Dorff, MD specialize in?
Tanya Dorff, MD focuses on Prostate Cancer and Skin Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are PSCA positive.
Is Tanya Dorff, MD currently recruiting for clinical trials?
Yes, Tanya Dorff, MD is currently recruiting for 6 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Tanya Dorff, MD has studied deeply?
Yes, Tanya Dorff, MD has studied treatments such as Abiraterone Acetate, Prednisone, Apalutamide.
What is the best way to schedule an appointment with Tanya Dorff, MD?
Apply for one of the trials that Tanya Dorff, MD is conducting.
What is the office address of Tanya Dorff, MD?
The office of Tanya Dorff, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.